Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
QuintilesIMS
Daiichi Sankyo
Merck
Queensland Health

Generated: July 18, 2019

DrugPatentWatch Database Preview

Patent: 6,825,035

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,825,035
Title: Compositions and methods for modulating expression within smooth muscle cells
Abstract:The present invention relates to promoters, enhancers and other regulatory elements that direct expression within SMC, comprising nucleotide sequences from the 5\' regulatory region and the first intron, and transcriptionally active fragments thereof, that control expression of an SM .alpha.-A. Specifically provided are expression vectors, host cells and transgenic animals wherein an SM .alpha.-A regulatory region is capable of controlling expression of a heterologous gene, over-expressing an endogenous SMC gene or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important for an SM-related disease in SMC. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of disorders involving SMC. The invention further relates to compositions and methods for modulating expression of compounds within SMC, and to screening compounds that modulate expression within SMC. Methods for using the molecules and compounds identified by the screening assays for therapeutic treatments also are provided.
Inventor(s): Owens; Gary K. (Earlysville, VA), Mack; Christopher (Chapel Hill, NC), Blank; Randall (Charlottesville, VA)
Assignee: Setagon, Inc. (Charlottesville, VA)
Application Number:09/807,757
Patent Claims:see list of patent claims

Details for Patent 6,825,035

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Try a Free Trial Setagon, Inc. (Charlottesville, VA) ➤ Try a Free Trial RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Try a Free Trial Setagon, Inc. (Charlottesville, VA) ➤ Try a Free Trial RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Try a Free Trial Setagon, Inc. (Charlottesville, VA) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Medtronic
Harvard Business School
Teva
Cantor Fitzgerald
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.